At week 12, remission rates were higher in the active-treatment groups (11.3%, 16.77%, 15.5%, and 5.7% for 7.5 mg, 22.5 mg, 75 mg, and 225 mg, respectively) in comparison with the placebo group (2.7%), although the 225 mg group did not reach statistical significance. 42 SHP647 was safe and well tolerated in both studies.
← all excerpts
New biologics and small molecules in inflammatory bowel disease: an update.
1
—
—